Natco seeks to block Gilead’s hepatitis C drug patent in India: source

(Reuters) – India’s Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc’s new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.

click to read more:

http://www.reuters.com/article/2014/04/10/us-natco-pharma-sovaldi-idUSBREA390VK20140410

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>